Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma.
about
Feasibility of intensity-modulated and image-guided radiotherapy for locally advanced esophageal cancer.Is there a benefit in receiving concurrent chemoradiotherapy for elderly patients with inoperable thoracic esophageal squamous cell carcinoma?Comparison of adverse effects of proton and X-ray chemoradiotherapy for esophageal cancer using an adaptive dose-volume histogram analysis.Predictive factors for acute radiation pneumonitis in postoperative intensity modulated radiation therapy and volumetric modulated arc therapy of esophageal cancer.Long-term results of chemoradiotherapy for stage II-III thoracic esophageal cancer in a single institution after 2000 -with a focus on comparison of three protocolsSymptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer.Radiation Therapy and Cardiac Death in Long-Term Survivors of Esophageal Cancer: An Analysis of the Surveillance, Epidemiology, and End Result DatabasePredictive factors for pericardial effusion identified by heart dose-volume histogram analysis in oesophageal cancer patients treated with chemoradiotherapyPredictive factors for radiation pneumonitis in oesophageal cancer patients treated with chemoradiotherapy without prophylactic nodal irradiation.Long-term outcome of irradiation with or without chemotherapy for esophageal squamous cell carcinoma: a final report on a prospective trialVEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinomaTrimodality therapy of esophagectomy plus neoadjuvant chemoradiotherapy improves the survival of clinical stage II/III esophageal squamous cell carcinoma patients.Preliminary treatment results of proton beam therapy with chemoradiotherapy for stage I-III esophageal cancer.Involved-field irradiation in definitive chemoradiotherapy for T4 squamous cell carcinoma of the esophagusEvaluation of radiation-induced myocardial damage using iodine-123 β-methyl-iodophenyl pentadecanoic acid scintigraphy.Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer.Long-term complications of definitive chemoradiotherapy for esophageal cancer using the classical methodComplications associated with postoperative adjuvant radiation therapy for advanced rectal cancer.High-dose versus conventional-dose irradiation in cisplatin-based definitive concurrent chemoradiotherapy for esophageal cancer: a systematic review and pooled analysis.Long-term outcome of concurrent chemoradiotherapy with elective nodal irradiation for inoperable esophageal cancer.Particle Radiation Therapy for Gastrointestinal Cancers.Value and application of trimodality therapy or definitive concurrent chemoradiotherapy in thoracic esophageal squamous cell carcinoma.Concurrent chemoradiotherapy with elective lymph node irradiation for esophageal cancer: a systemic review and pooled analysis of the literature.Proton beam therapy in Japan: current and future status.Bayesian regression analyses of radiation modality effects on pericardial and pleural effusion and survival in esophageal cancerDihydroartemisinin improves the efficiency of chemotherapeutics in lung carcinomas in vivo and inhibits murine Lewis lung carcinoma cell line growth in vitro.Symptomatic radiation-induced cardiac disease in long-term survivors of esophageal cancer.Dosimetric predictors of radiation-induced pericardial effusion in esophageal cancer.Treatment with Corticosteroid for Pericardial Effusion in a Patient with Advanced Synchronous Esophageal and Gastric Cancers following Chemoradiotherapy.Clinical outcomes of intensity modulated proton therapy and concurrent chemotherapy in esophageal carcinoma: a single institutional experience.The impact of radiation therapy sequencing on survival and cardiopulmonary mortality in the combined modality treatment of patients with esophageal cancer.Radiotherapy for esophageal cancer using simultaneous integrated boost techniques: dosimetric comparison of helical TomoTherapy, Volumetric-modulated Arc Therapy (RapidArc) and dynamic intensity-modulated radiotherapy.Constrictive Pericarditis 5 Months after Radiation Therapy in a 62-Year-Old Woman with Esophageal Cancer.Dosimetric comparison between proton beam therapy and photon radiation therapy for locally advanced esophageal squamous cell carcinoma.The evolution of proton beam therapy: Current and future status.Clinical characteristics and dose-volume histogram parameters associated with the development of pleural effusions in non-small cell lung cancer patients treated with chemoradiation therapy.Esophagectomy for superficial esophageal cancer after non-curative endoscopic resection.Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.Does pre-operative estimation of oesophageal tumour metabolic length using 18F-fluorodeoxyglucose PET/CT images compare with surgical pathology length?
P2860
Q30413693-66331997-6AD1-4CEE-AFF3-3AB940E9E2DDQ34061742-BB3C4CDB-8AC4-43F7-9156-4AB3AA6A58C9Q35591822-07460B9E-8C1A-4470-B250-3B2ADB36CC5DQ35663484-41847D4E-EAFB-4E31-B148-6FC49F4364F3Q35823373-B17867EF-C5C4-48AF-A920-05B0C58882FAQ36074242-509CB035-9A1B-483E-95C1-D834838D359EQ36080134-39FE2958-65C0-40C1-A997-F2609B4868FFQ36187160-B904B044-3B84-4B9A-AB2C-B53C025EE1D2Q36326303-A979E53B-4B55-416A-AA45-CEE75B76B9C6Q36388206-28B41026-3E38-4C9A-8BA8-7BC18D87D264Q36400850-1D810E2B-6D3B-4B22-87CF-11B5DCBCB23DQ36642770-76908677-9DA4-4140-B506-0B573381EBC9Q36706857-F5CB2A0B-B872-4A65-8400-D2322B897694Q36807919-00F5F3CA-C5A2-4624-BE70-D938741559C1Q37154052-C89775F4-0AE1-43D7-9989-0B5E280A6E5EQ37582498-94547ECB-311A-4DA2-9380-C9AD1324446AQ37659287-3BCDA6B7-FB43-473A-9A75-70A323CFABB5Q37670877-11691125-D932-401B-9584-F83AE0430DB2Q38559388-84380DBD-3AF4-4008-8742-079BCDBB7191Q38700573-6A7CFEF3-1A67-4584-9FAC-EF89832EC79EQ38724284-37818FAF-A0FB-49D2-8002-D4BE6B6A0D11Q38728084-4B359447-D832-454C-8CEA-EC144CD51BEFQ38751417-352B84A8-C134-410E-AEE2-BF8F0F4B58AFQ38830371-A889D5B5-E189-4A75-9086-973784348895Q39452568-E387E5E0-B2F7-4DDC-BBC2-1E245D84EDCEQ39799226-3DBAC382-DE27-494D-8378-870A4C090B59Q39992067-4D9C8B2C-6398-4A5B-B357-60A0BEDCEAB4Q40235388-549A386B-91ED-4734-BB8E-AA45A3B70217Q41912688-D4E45D76-969C-4749-ACC7-6206F4EAB645Q43379663-EEF7772A-0D84-4C2C-B154-1F06B04353B8Q44932649-93DD46B3-DAD4-4F42-BC32-9E75F94277B9Q45899297-E7F886D2-9AEC-49BB-B7C7-319103D437D3Q47157268-9F4DEFD6-6DB2-47C1-B4A6-2B8B4B7CCBA0Q49264304-2C9B04AF-6994-4BDA-8001-B146E235D461Q49333936-208AA14D-AAEA-4F11-9A50-56732C105149Q49466057-6A99E071-4348-44C8-9944-B9CF6E586D7DQ51064997-0964B5FE-447B-4C74-BBD2-9D5CAFCC7315Q51250976-3175E6A0-7675-4411-B4ED-D3C53B5F2B2CQ53255081-F400F7AD-0FD8-4B18-A529-05176EDCD4FC
P2860
Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Late toxicity after definitive ...... thoracic esophageal carcinoma.
@en
Late toxicity after definitive ...... thoracic esophageal carcinoma.
@nl
type
label
Late toxicity after definitive ...... thoracic esophageal carcinoma.
@en
Late toxicity after definitive ...... thoracic esophageal carcinoma.
@nl
prefLabel
Late toxicity after definitive ...... thoracic esophageal carcinoma.
@en
Late toxicity after definitive ...... thoracic esophageal carcinoma.
@nl
P2093
P1476
Late toxicity after definitive ...... thoracic esophageal carcinoma.
@en
P2093
Keisho Chin
Kotaro Gomi
Madoka Morota
Masaaki Matsuura
Masahiko Oguchi
Takashi Yamashita
Takuyo Kozuka
P304
P356
10.1016/J.IJROBP.2008.10.075
P407
P577
2009-03-26T00:00:00Z